Long-Acting Injectable Antiretroviral Therapy in Medicare-Enrolled Adults With HIV

1

Long-acting injectable antiretroviral therapy (LA-ART) offers sustained viral suppression for HIV patients without daily pill adherence.
2

Uptake of LA-ART among Medicare beneficiaries with HIV was low, reaching only 3.0% by 2023, highlighting disparities in access.
3

Older patients and those with complex chronic conditions were less likely to receive LA-ART, possibly due to clinician concerns.
4

Dual-eligible beneficiaries and Medicare Advantage enrollees were more likely to receive LA-ART, indicating access and affordability issues.
5

Higher LA-ART use among beneficiaries with mental health disorders suggests potential benefits for adherence challenges in this population.

Jama Network Open

by Jose F. Figueroa, Rebekah I. Stein, Jessica Phelan, E. John Orav, Grace Luu, Shibani S. Mukerji, Emily P. Hyle
June 12, 2026

1